PARP Inhibitor in Platinum-Resistant Ovarian Cancer: Single-Center Real-World Experience

PURPOSE: Poly (ADP-ribose) polymerase inhibitors (PARPi) have proven efficacy in treatment of BReast CAncer (BRCA) gene mutation-positive platinum-sensitive ovarian cancers. There is paucity of data for their role in platinum-resistant ovarian cancer (PROC). We report here retrospective analysis of...

Descripción completa

Detalles Bibliográficos
Autores principales: Agarwal, Amit, Baghmar, Saphalta, Dodagoudar, Chandragouda, Qureshi, Suhail, Khurana, Aseem, Vaibhav, Vikas, Kumar, Guresh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8162970/
https://www.ncbi.nlm.nih.gov/pubmed/33852339
http://dx.doi.org/10.1200/GO.20.00269

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8162970/
https://www.ncbi.nlm.nih.gov/pubmed/33852339
http://dx.doi.org/10.1200/GO.20.00269

Ejemplares similares